When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study ...

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus ...

All four members of hololive English -Justice- will be hosting a panel followed by individual Meet & Greet sessions on Friday, May 23, 2025. Hakos Baelz, Fuwawa Abyssgard, and Mococo Abyssgard ...

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

Gifting allows recipients to access the article for free. Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data licensing and model development fees. Tempus AI has invested heavily ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services ...

BTIG just kicked off coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and a $60 price target suggesting nearly 48% upside from where the stock trades now. Analyst Mark Massaro called the ...

As previously reported, BTIG initiated coverage of Tempus AI (TEM) with a Buy rating and $60 price target Tempus AI is a rapidly growing precision medicine platform technology company, which has ...